Synthesis and pharmacology of a novel pyrrolo[2,1,5-cd] indolizine (NNC 45-0095), a high affinity non-steroidal agonist for the estrogen receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 4, 2000, Pages 399-402

  Jorgensen A S ^a   Jacobsen, P ^a   Christiansen, L B ^a   Bury, P S ^a   Kanstrup, A ^a   Thorpe, S M ^a   Bain, S ^b   Naerum L ^a   Wassermann, K ^a  

^a NOVO NORDISK A S   (Denmark)

^b SkeleTech Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ETHYL 2 4 HYDROXYPHENYLPYRROLO[2,1,5 CD]INDOLIZINE; ESTRADIOL; ESTROGEN RECEPTOR; INDOLIZINE DERIVATIVE; MOXESTROL; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BONE; BONE ATROPHY; CELL PROLIFERATION; CLIMACTERIUM; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; MOUSE; NONHUMAN; PHARMACOPHORE; UTERUS;

ANIMALS; BINDING, COMPETITIVE; BIOLOGICAL ASSAY; BONE DENSITY; CYTOSOL; DISEASE MODELS, ANIMAL; DRUG EVALUATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; INDOLIZINES; INHIBITORY CONCENTRATION 50; MICE; MYOMETRIUM; PYRROLES; RABBITS; RATS; RECEPTORS, ESTROGEN;

ANIMALIA;

EID: 0034696378     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00015-9     Document Type: Article

References (21)

1. Smith E.P., Boyd J., Frank G.R., Takahashi H., Cohen R.M., Specker B., Williams T.C., Lubahn D.B., Korach K.S. N. Engl. J. Med. 331:1994;1056.
2. Carani C., Qin K., Simoni M., Faustinifustini M., Serpente S., Boyd J., Korach K.S., Simpson E.R. N. Engl. J. Med. 337:1997;91.
3. Cosman, F.; Dempster, D.; Lindsay, R. In Estrogen and Antiestrogens. Basic and Clinical Aspects; Lindsay, R.; Dempster, D. W.; Jordan, V. C., Eds.; Lippincott-Raven: Philadelphia, 1997, pp 151-164.
4. Sherwin, B. B. In Estrogen and Antiestrogens. Basic and Clinical Aspects; Lindsay, R.; Dempster, D. W.; Jordan, V. C., Eds.; Lippincott-Raven: Philadelphia, 1997, pp 75-87.
5. Farhat M.Y., Lavigne M.C., Ramwell P.W. FASEB J. 10:1996;615.
6. Lobo, R. A. In Estrogen and Antiestrogens. Basic and Clinical Aspects; Lindsay, R.; Dempster, D. W.; Jordan, V. C., Eds.; Lippincott-Raven, Philadelphia, 1997, pp 63-72.
7. Colditz G.A., Hankinson S.E., Hunter D.J., Willett W.C., Manson J.E., Stampfer M.J., Hennekens C., Rosner B., Speizer F.E. N. Engl. J. Med. 332:1995;1589.
8. Stanford J.L., Weiss N.S., Voigt L.F., Daling J.R., Habel L.A., Rossing M.A. JAMA. 274:1995;137.
9. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., Draper M., Christiansen C. N. Engl. J. Med. 337:1997;1641.
10. Nuttall M.E., Bradbeer J.N., Stroup G.B., Nadeau D.P., Hoffman S.J., Zhao H., Rehm S., Gowen M. Endocrinology. 139:1998;5224.
11. Ke H.Z., Paralkar V.M., Grasser W.A., Crawford D.T., Qi H., Simmons H.A., Pirie C.M., Chidseyfrink K.L., Owen T.A., Smock S.L., Chen H.K., Jee W.S.S., Cameron K.O., Rosati R.L., Brown T.A., Dasilvajardine P., Thompson D.D. Endocrinology. 139:1998;2068.
12. Tschitschibabin A.E. Chem. Ber. 60:1927;1607.
13. 15NO: C, 82.73; H, 5.79; N, 5.36%. Found: C, 83.03; H, 5.88; N, 5.16%.
14. Thorpe S.M. Breast Cancer Res. Treat. 9:1987;175.
15. Littlefield B.A., Gurpide E., Markiewicz L., McKinley B., Hochberg R.B. Endocrinology. 127:1990;2757.
16. Terenius L. Acta Endocrinol. (Copenh). 66:1971;431.
17. Odum J., Lefevre P.A., Tittensor S., Paton D., Routledge E.J., Beresford N.A., Sumpter J.P., Ashby J. Regul. Toxicol. Pharmacol. 25:1997;176.
18. Eiken P., Kolthoff N., Nielsen S.P. Bone. 19:1996;191S.
19. Wronski T.J., Cintron M., Doherty A.L., Dann L.M. Endocrinology. 123:1988;681.
20. Bain S.D., Bailey M.C., Celino D.L., Lantry M.M., Edwards M.W. J. Bone Min. Res. 8:1993;435.
21. Keenan M.J., Hegsted M., Reisenauer A.M., Ward T.L., Southern L.L. J. Bone Min. Res. 7:1992;247.